Loading…
← CockpitCompetitor Analysis › 603122.SS Cowealth Medical China Co., Ltd. Class AOpen in the cockpit ↗

Cowealth Medical China Co., Ltd. Class A603122.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum weak 25
Mkt cap
$562M
US dollars, full cap
$/day
$41.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-6.0 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥9.61
1D-2.7%
1W-19.7%
1M-15.9%
3M-23.1%
6M-33.6%
YTD-60.6%
1Y+8.0%
ATR %8.0%
52w lowhigh69.2% off high

What Cowealth Medical China does

Employees: 161

Cowealth Medical China at a glance

Size Cowealth Medical China (603122.SS) is a China Health Care company (Medical Specialties) with a market value of $562M, the 3414th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.61 on 18 Nov 2026.

Performance Over six months the shares fell 33.6%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 17.6% over the last twelve months (peer median +14.4%); the operating margin is -5.3% (peer median 6.5%).

Valuation It trades at 5.9× enterprise value to sales against a peer median of 5.5× (9th most expensive of 19).

Capital Return on invested capital runs 6.0 points below its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 99603122.SS 67
Six months, rebased to 100: Cowealth Medical China against the median of its 20 peers (local-currency closes).

Cowealth Medical China financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥640MCN¥677MCN¥937MCN¥1.09BCN¥1.28B
Revenue growth—-28%-14%-15%—
Gross profitCN¥121MCN¥89.2MCN¥172MCN¥214MCN¥245M
EBITDAn/a-CN¥16.7MCN¥49.8MCN¥73.6MCN¥122M
Net income-CN¥26.9M-CN¥33.6MCN¥27.6MCN¥47.2MCN¥82.7M
Free cash flow-CN¥76.9MCN¥6.19MCN¥103M-CN¥57.2M-CN¥54.3M
Capital expenditureCN¥11.7MCN¥14.2MCN¥31.8MCN¥68.0MCN¥25.9M
Total debtCN¥188MCN¥170MCN¥122MCN¥72.2MCN¥140M

Quarterly statements and history in the cockpit →

Cowealth Medical China competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-100%0%+100%+200%+300%0%+50%301235PACB300952300869605369OBIO300314688581TCMDZJYLMYGNRCELSGHTNNNN603122.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Cowealth Medical China is the large dot.

Fundamentals: revenue growth against valuation

0%+250%+500%+750%+1,000%0×10×20×301235PACB300952300869605369OBIOTCMDZJYLVVVV603122.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cowealth Medical China is the large dot.

Cowealth Medical China competitors and peer comparison

How Cowealth Medical China compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cowealth Medical China against its 20 peers (data as of 18 Nov 2026)
Measure603122.SSPeer medianRank in peer set
1-month return-15.9%-0.8%2nd lowest of 19
6-month return-33.6%+1.1%4th lowest of 19
Distance from 52-week high-69.2%-31.6%2nd lowest of 20
Revenue growth (TTM)-17.6%+14.4%2nd lowest of 20
Operating margin-5.3%6.5%8th lowest of 20
EV / Sales5.9×5.5×9th most expensive of 19
ROIC minus cost of capital-6.0 pp-3.3 pp7th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cowealth Medical China 603122.SSChina$562M-34%-18%-5%5.9×n/an/a
Wuhan Huakang Century Clean Technology 301235.SZChina$563M-57%+28%7%1.6×n/an/a
Pacific Biosciences of California PACBUnited States$573M+54%+4%-98%6.7×n/an/a
Jiangsu Hanvo Safety Product 300952.SZChina$575M-38%+6%8%3.3×n/an/a
Contec Medical Systems 300869.SZChina$547M-26%-2%-16%5.5×15.0%-19.8%
Zhejiang Gongdong Medical Technology 605369.SSChina$542M-21%+6%9%2.6×10.2%+6.5%
Orchestra BioMed OBIOUnited States$587M+87%+1,007%-195%18.3×n/an/a
Ningbo David Medical Device 300314.SZChina$589M+25%+19%11%5.4×n/an/a
Hangzhou AGS MedTech 688581.SSChina$590M-22%-18%33%3.7×0.4%+27.8%
Tactile Systems Technology TCMDUnited States$592M+6%+14%9%1.5×8.4%+12.0%
Jin Medical International ZJYLUnited States$532M+47%-14%2%26.5×n/an/a
vVARDIS VVVVUnited States$594Mn/a+148%-72%14.3×n/an/a
Myriad Genetics MYGNUnited States$530M+45%-3%-13%0.8×n/an/a
Sahajanand Medical Technologies SMT.NSIndia$595Mn/an/an/an/an/an/a
AVITA Medical RCELUnited States$529M+290%+17%-34%6.7×n/an/a
Sight Sciences SGHTUnited States$599M+122%+16%-30%6.4×n/an/a
Medistim MEDI.OLNorway$599M+32%+19%29%7.1×-1.2%+14.5%
Nanosonics NAN.AXAustralia$599M-4%+3%7%3.8×35.3%+6.7%
MedicalSystem Biotechnology 300439.SZChina$518M-9%+14%2%1.5×6.0%-7.7%
Anbio Biotechnology NNNNUnited States$518M-89%+10%67%n/an/an/a
Xvivo Perfusion XVIVO.STSweden$611M-32%+18%12%6.3×35.9%+35.2%

Questions

Which companies are Cowealth Medical China's closest peers?
The cockpit's peer set: Wuhan Huakang Century Clean Technology (301235.SZ), Pacific Biosciences of California (PACB), Jiangsu Hanvo Safety Product (300952.SZ), Contec Medical Systems (300869.SZ), Zhejiang Gongdong Medical Technology (605369.SS), Orchestra BioMed (OBIO), Ningbo David Medical Device (300314.SZ), Hangzhou AGS MedTech (688581.SS).
Is Cowealth Medical China expensive compared with its peers?
On ev / sales it trades at 5.9× against a peer median of 5.5×, 9th most expensive of 19 in its peer set.
How has Cowealth Medical China stock performed?
Over six months to 18 Nov 2026 the shares returned -33.6% against +1.1% for the median peer; over one year +8.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.